- April 15th, 2019 : Achaogen (NASDAQ: AKAO) wants to sell itself through an auction as a part of a Chapter 11 bankruptcy reorganization.
- Shares of Achaogen have traded under $1 since Feb. 15.
Achaogen, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections. The company is principally developing plazomicin, which has completed Phase II clinical trials for the treatment of bacterial infections due to multi-drug resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal programs that target infections caused by Pseudomonas aeruginosa. Achaogen, Inc. was incorporated in 2002 and is headquartered in South San Francisco, California.
Address
7000 SHORELINE COURT SUITE 371
SOUTH SAN FRANCISCO, CA 94080
United States
SOUTH SAN FRANCISCO, CA 94080
United States
Website
www.achaogen.comKey stats and ratios
| Q1 (Mar '14) | 2013 | |
| Net profit margin | -57.70% | -70.83% |
| Operating margin | -54.01% | -64.63% |
| EBITD margin | - | -61.89% |
| Return on average assets | -24.59% | -77.08% |
| Return on average equity | - | - |
| Employees | 39,000 |
No comments:
Post a Comment